KalVista Pharmaceuticals, Inc. Common Stock
KALVStock
$27.00+53.48%52W
Market Cap$1.44B
P/E—
Div yield—
Beta-0.15
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)78.10%
Price vs S&P 500 (4W)3.02%
VGM Score60.79
Market Capitalization$1.44B
Earnings Surprise History
Q1 26-0.43est. -0.48
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
3.92
3.69
3.69
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KALVKalVista Pharmaceuticals, Inc. Common Stock | D | B | A | $27.00 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
KalVista Pharmaceuticals develops oral small-molecule therapies targeting the kallikrein-kinin system for rare genetic and acquired disorders with significant unmet medical needs. The company's commercial product, EKTERLY (sebetralstat), is an FDA-approved plasma kallikrein inhibitor for acute hereditary angioedema (HAE) attacks in patients aged 12 and older. Leveraging its novel oral drug discovery platform, KalVista is positioned to address multiple orphan indications in disease areas with limited treatment options.